ArticleBMC public health2026
Association between modified a body shape index and incident cognitive impairment in middle-aged and older adults: a prospective cohort study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCentral obesity contributes significantly to cognitive decline. Traditional indices like BMI inadequately capture visceral adiposity and exhibit the obesity paradox in elderly populations.This study looked into the connection between a modified A Body Shape Index (ABSI) and the development of cognitive impairment in middle-aged and older adults.
methodsLongitudinal data from 4,353 eligible participants in the 2011-2020 CHARLS cohort were analyzed. Modified ABSI was calculated based on waist circumference, BMI, and height and categorized into quartiles. Cox proportional hazards regression models were used to evaluate the association between modified ABSI and incident cognitive impairment. The fully adjusted model included age, sex, residence, education, marital status, smoking, drinking, hypertension, diabetes mellitus, dyslipidemia, stroke, heart disease, systolic and diastolic blood pressure, triglycerides, LDL-C, HDL-C, HbA1c, CRP, serum creatinine, and uric acid. Restricted cubic spline, subgroup, and sensitivity analyses were also performed.
resultsOver the follow-up period, cognitive impairment occurred in 1,822 participants, corresponding to 41.9% of the study population. In the Cox model that was fully adjusted, individuals in the highest ABSI quartile (Q4) exhibited a markedly elevated hazard of cognitive impairment relative to those in the lowest quartile (Q1) (HR = 1.22, P = 0.024). A pronounced dose-response pattern was evident, which persisted as statistically significant and linear following comprehensive covariate adjustment (P = 0.037). Subgroup analyses indicated more pronounced associations among female participants and individuals aged 70 years or older (P < 0.05).
conclusionHigh ABSI levels are significantly associated with an increased long-term risk of cognitive impairment in middle-aged and older adults. The findings suggest that ABSI could serve as an effective surrogate marker for central adiposity, facilitating the early recognition of individuals at heightened risk for cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.